Over the weekend, GW Pharmaceuticals PLC – ADR GWPH presented additional data from its Phase III trials of Epidiolex in Lennox-Gastaut (LGS) and Dravet syndromes, at the American Epilepsy Society (AES) meeting.
Cantor Fitzgerald’s Elemer Piros maintained a Buy rating on the company, with a price target of $182.
Phase III Data
Piros mentioned that “both studies achieved robust reductions of their primary endpoint in drop seizures and convulsive seizures, respectively.”
Responder analyses presented by GW Pharma at the AES meeting showed that Epidiolex was successful in achieving significant separations from the placebo group.
For Dravet, while responder analyses was marginally short of statistical significant, the analyst noted that “separation was maintained along the curves,” while the safety data demonstrated “a greater incidence of somnolence, diarrhea and decreased appetite in Dravet, compared with LGS.”
Piros believes that overall, the data highlighted Epidiolex’s significant ability to treat two orphan pediatric epilepsy indications, with distinct patient population characteristics.
The stock closed Friday's session at $112.32, up nearly 3 percent.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.